CD8A and neoplasm: Thus, STACT was created from the parental VNP20009 strain through genome engineering to attenuate TLR-mediated production of systemic proinflammatory cytokines and eliminate bacterial features that cause immunosuppression of CD8+ T-cell responses, enabling higher dosing in the clinic to achieve tumor colonization.